Mechanism Diligence

Clear science. Informed decisions.

Mechanism Review

Want us to review the evidence behind your mechanism?

See examples below and contact us.

Contact us →See examples ↓

A new drug pair needs its own evidence.

✓ Supported

Tested pair

AB
Fewer cell groups grew.

Versus A alone, in this lab test.

? Not supported

New pair

AC
Result unknown.

This study does not tell us.

Leukemia cells in a lab—not a test in patients. Illustration, not measured data.
A = imatinib · B = chloroquine · C = a proposed new drug.
“Not supported” means not shown by this study. It does not mean the new pair cannot work.

Sample case, not client work. Scientific review pending.

Why this matters

The study already checked cells after the drugs were removed. The missing piece is evidence for the new drug pair.

Our next-step advice: check the new pair’s data first. If key evidence is missing, fill that gap before funding a larger animal study.

A proposed next step for this sample case.

Start with one figure

  1. 1Check its claims
  2. 2Trace the sources
  3. 3Recommend next steps

You get a marked figure, checked claims with sources, and a short written recommendation.

We agree on the scope and fee before work starts.

See the evidence and review

This is a focused sample, not a full review of a drug.

Claim register

Evidence, conditions and revised wording
01 · Published resultRetain with conditions
Finding
Imatinib + chloroquine reduced long-term culture-initiating cell (LTC-IC) output about 4.5-fold versus imatinib alone, with growth factors.
Conditions
Three CML samples; imatinib 2 µM + chloroquine 10 µM for six days, then washout and long-term culture. Figure 8D and methods ↗
Interpretation
Functional evidence after drug removal. It does not establish stem-cell eradication in patients.
02 · Transfer to a new compoundNot established
Claim
“These results justify efficacy testing of our combination.”
Missing evidence
Does our compound affect the intended pathway and reduce durable CML cell function at feasible exposure, with separation from normal-cell toxicity? No candidate data were supplied.
Use instead
“The published combination supports the rationale. Our compound’s exposure and functional evidence will determine the next study.”

Decision memo

Proposed study and decision limits
Check first
Review existing candidate data before ordering more experiments. If the bridge is already supported, assess the efficacy study on that evidence.
If missing
Run a focused exposure–response study: candidate alone, imatinib alone and the combination, with vehicle controls. Link pathway activity to post-washout CML function and normal blood-forming cell function at matched exposures.
Advance when
Mechanism-consistent activity and functional benefit over either drug alone occur at a feasible exposure, with a credible normal-cell margin.
Hold when
The effect requires implausible exposure or tracks general toxicity. More efficacy work alone would not resolve that problem.

Illustrative recommendation. Agree assays, exposure benchmarks and decision thresholds from the actual compound and intended model.

Sources and review status

This focused example builds on C03/C04/C08 of sample MD-MER-CML-AUTO-002, v2.2. It is not a full literature review or asset assessment. Bellodi’s study already includes washout and normal-cell experiments; neither establishes a new compound’s therapeutic margin. The supplement has not been independently appraised here.

Biomarker interpretation: LC3 accumulation alone cannot distinguish increased autophagosome formation from blocked clearance. Select flux controls for the compound’s mechanism; do not treat a static LC3 signal as direct target engagement.

The paper’s 2013 correction concerns Figure 1D, not the Figure 8 result used here. Prepared with AI assistance. Independent review remains open: mechanism and exposure (H2), functional assays (H3), experiment priorities (H5), and final wording and figure (H6). The full sample’s other review gates remain open.

Primary paper, methods and amendment history ↗

What do you want to find out?

Shashank Shrishrimal, Ph.D.Reads every inquiry

Experience in drug discovery, drug development and biomarker analysis.

No confidential or patient information, please.

Or email Shashank.